Do We Really Need Routine CYP2C19 Genotyping?
- 4 May 2020
- journal article
- letter
- Published by Elsevier BV in JACC: Cardiovascular Interventions
- Vol. 13 (9), 1134-1135
- https://doi.org/10.1016/j.jcin.2020.03.034
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMIJACC: Cardiovascular Interventions, 2020
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSEuropean Heart Journal, 2017
- Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trialInternational Journal of Cardiology, 2015
- Pharmacodynamic Effect of Switching Therapy in Patients With High On-Treatment Platelet Reactivity and Genotype Variation With High Clopidogrel Dose Versus PrasugrelCirculation: Cardiovascular Interventions, 2012